Amarin Corporation plc (AMRN) 10-Year Financial Performance & Capital Metrics

AMRN • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

AboutAmarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Show more

Revenue $229M -25.5%
EBITDA -$89M -37.4%
Net Income -$82M -39.0%
EPS (Diluted) -0.20 -33.3%
Gross Margin 35.6% -34.0%
EBITDA Margin -38.84% -84.4%
Operating Margin -40.15% -82.3%
Net Margin -35.95% -86.6%
ROE -15.83% -53.6%
ROIC -18.75% -38.6%
Debt/Equity 0.02 +0.4%
Interest Coverage -13113.86 -55.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 11.9% over 5 years
✗Expensive at 12.8x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y15.48%

5Y-11.86%

3Y-26.81%

TTM-6.67%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-118.79%

EPS CAGR

10Y-

5Y-

3Y-

TTM-910.42%

ROCE

10Y Avg-33.06%

5Y Avg-9.16%

3Y Avg-14.77%

Latest-17.03%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.99B	41.39	532.01		31.18%	-33.24%	3.76%	0.14
GNFTGenfit S.A.	310.02M	6.20	206.67	134.56%	-14.12%	-31.42%	4.59%	0.90
GYREGyre Therapeutics, Inc.	750.44M	7.79	155.80	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.78M	4.56	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	129.59M	6.03	-1.08	-100%		-89.15%		0.10
GLTOGalecto, Inc.	37.28M	23.30	-1.26			-237.68%		0.00
IVAInventiva S.A.	1.1B	5.71	-1.61	-47.37%	-13.75%
GALTGalectin Therapeutics Inc.	197.93M	3.07	-4.04

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	81.76M	130.08M	181.1M	229.21M	429.75M	614.06M	583.19M	369.19M	306.91M	228.61M
Revenue Growth %	0.51%	0.59%	0.39%	0.27%	0.87%	0.43%	-0.05%	-0.37%	-0.17%	-0.26%
Cost of Goods Sold+	27.88M	34.36M	44.95M	54.54M	96.02M	131.44M	121.33M	126.71M	141.37M	147.23M
COGS % of Revenue	0.34%	0.26%	0.25%	0.24%	0.22%	0.21%	0.21%	0.34%	0.46%	0.64%
Gross Profit+	53.88M	95.72M	136.15M	174.67M	333.74M	482.62M	461.86M	242.48M	165.54M	81.38M
Gross Margin %	0.66%	0.74%	0.75%	0.76%	0.78%	0.79%	0.79%	0.66%	0.54%	0.36%
Gross Profit Growth %	0.6%	0.78%	0.42%	0.28%	0.91%	0.45%	-0.04%	-0.47%	-0.32%	-0.51%
Operating Expenses+	152.1M	161.35M	181.71M	282.9M	358.01M	502.27M	451.36M	348.35M	233.13M	173.18M
OpEx % of Revenue	1.86%	1.24%	1%	1.23%	0.83%	0.82%	0.77%	0.94%	0.76%	0.76%
Selling, General & Admin	101.05M	111.37M	134.55M	227M	323.62M	463.31M	408.33M	304.42M	199.94M	152.31M
SG&A % of Revenue	1.24%	0.86%	0.74%	0.99%	0.75%	0.75%	0.7%	0.82%	0.65%	0.67%
Research & Development	51.06M	49.98M	47.16M	55.9M	34.39M	38.96M	29.31M	30.41M	22.22M	20.87M
R&D % of Revenue	0.62%	0.38%	0.26%	0.24%	0.08%	0.06%	0.05%	0.08%	0.07%	0.09%
Other Operating Expenses	-9K	-482K	74K	-326K	0	104K	13.72M	13.53M	10.97M	0
Operating Income+	-98.22M	-65.63M	-45.55M	-108.22M	-24.28M	-19.66M	10.5M	-105.87M	-67.59M	-91.8M
Operating Margin %	-1.2%	-0.5%	-0.25%	-0.47%	-0.06%	-0.03%	0.02%	-0.29%	-0.22%	-0.4%
Operating Income Growth %	-0.02%	0.33%	0.31%	-1.38%	0.78%	0.19%	1.53%	-11.08%	0.36%	-0.36%
EBITDA+	-97.41M	-64.85M	-44.84M	-107.56M	-23.42M	-17.6M	13.36M	-102.77M	-64.62M	-88.78M
EBITDA Margin %	-1.19%	-0.5%	-0.25%	-0.47%	-0.05%	-0.03%	0.02%	-0.28%	-0.21%	-0.39%
EBITDA Growth %	-0.02%	0.33%	0.31%	-1.4%	0.78%	0.25%	1.76%	-8.69%	0.37%	-0.37%
D&A (Non-Cash Add-back)	812K	777.59K	715.59K	667.87K	859K	2.05M	2.86M	3.1M	2.96M	3.01M
EBIT	-98.11M	-57.31M	-45.05M	-107.3M	-15.86M	-14.76M	11.42M	-103.79M	-53.88M	-77.19M
Net Interest Income+	-20.05M	-18.44M	-9.34M	-7.8M	1.87M	2.3M	1.09M	2.8M	11.86M	13.4M
Interest Income	0	234K	429K	1.07M	8.5M	4.9M	1.22M	2.82M	11.86M	13.4M
Interest Expense	20.05M	18.68M	9.77M	8.87M	6.63M	2.6M	129K	15K	8K	7K
Other Income/Expense	-20.07M	-10.76M	-9.26M	-8.12M	1.8M	2.4M	789K	2.06M	13.92M	14.6M
Pretax Income+	-118.29M	-76.38M	-55.41M	-116.35M	-22.48M	-17.25M	11.29M	-103.81M	-53.67M	-77.2M
Pretax Margin %	-1.45%	-0.59%	-0.31%	-0.51%	-0.05%	-0.03%	0.02%	-0.28%	-0.17%	-0.34%
Income Tax+	-3.09M	9.97M	13.05M	96K	164K	745K	3.56M	2M	5.44M	4.98M
Effective Tax Rate %	0.97%	1.13%	1.22%	1%	1.01%	1.04%	0.68%	1.02%	1.1%	1.06%
Net Income+	-115.2M	-86.35M	-67.86M	-116.44M	-22.64M	-18M	7.73M	-105.8M	-59.11M	-82.18M
Net Margin %	-1.41%	-0.66%	-0.37%	-0.51%	-0.05%	-0.03%	0.01%	-0.29%	-0.19%	-0.36%
Net Income Growth %	-1.04%	0.25%	0.21%	-0.72%	0.81%	0.21%	1.43%	-14.69%	0.44%	-0.39%
Net Income (Continuing)	-115.2M	-86.35M	-68.59M	-116.44M	-22.64M	-18M	7.73M	-105.8M	-59.11M	-82.18M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.83	-0.41	-0.25	-0.39	-0.07	-0.05	0.02	-0.26	-0.15	-0.20
EPS Growth %	-1.31%	0.51%	0.39%	-0.56%	0.83%	0.24%	1.38%	-14.54%	0.42%	-0.33%
EPS (Basic)	-0.83	-0.41	-0.25	-0.39	-0.07	-0.05	0.02	-0.26	-0.15	-0.20
Diluted Shares Outstanding	180.65M	211.87M	270.65M	297.24M	342.54M	381.76M	402.48M	401.15M	407.65M	410.94M
Basic Shares Outstanding	179.59M	210.61M	270.65M	297.24M	342.54M	360M	395.99M	401.15M	394.08M	410.94M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	143.52M	146.33M	153.27M	378M	855M	879.23M	878.73M	689.1M	724.98M	595.4M
Cash & Short-Term Investments	106.96M	98.25M	73.64M	249.23M	644.59M	500.93M	454.13M	309.36M	320.66M	294.22M
Cash Only	106.96M	98.25M	73.64M	249.23M	644.59M	186.96M	219.45M	217.67M	199.25M	121.04M
Short-Term Investments	0	0	0	0	0	313.97M	234.67M	91.69M	121.41M	173.18M
Accounts Receivable	13.83M	19.98M	45.32M	66.52M	116.43M	154.57M	163.65M	130.99M	133.56M	122.28M
Days Sales Outstanding	61.73	56.08	91.33	105.93	98.89	91.88	102.43	129.5	158.84	195.23
Inventory	18.98M	20.51M	30.26M	57.8M	76.77M	188.86M	234.68M	228.73M	258.62M	166.05M
Days Inventory Outstanding	248.59	217.82	245.7	386.81	291.82	524.45	706	658.89	667.71	411.65
Other Current Assets	600K	600K	600K	1.5M	3.91M	3.92M	3.92M	20.02M	525K	12.85M
Total Non-Current Assets+	29.94M	20.67M	8.33M	7.72M	27.2M	86.79M	189.34M	197.08M	106.7M	89.95M
Property, Plant & Equipment	243K	78K	28K	63K	10.87M	10.07M	9.09M	9.95M	8.42M	7.61M
Fixed Asset Turnover	336.44x	1667.74x	6468.00x	3638.32x	39.53x	60.98x	64.19x	37.11x	36.43x	30.05x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	9.42M	8.77M	8.13M	7.48M	15.26M	13.82M	23.55M	21.78M	19.3M	16.39M
Long-Term Investments	0	0	-1.74M	0	0	62.47M	35M	1.27M	0	0
Other Non-Current Assets	2.04M	741K	174K	174K	1.07M	432K	121.71M	164.08M	78.97M	65.95M
Total Assets+	173.46M	167M	161.6M	385.71M	882.21M	966.02M	1.07B	886.18M	831.68M	685.35M
Asset Turnover	0.47x	0.78x	1.12x	0.59x	0.49x	0.64x	0.55x	0.42x	0.37x	0.33x
Asset Growth %	0.01%	-0.04%	-0.03%	1.39%	1.29%	0.1%	0.11%	-0.17%	-0.06%	-0.18%
Total Current Liabilities+	50.72M	76.25M	108.53M	157.26M	242.25M	307.44M	370.68M	259.48M	259.28M	179.95M
Accounts Payable	10.83M	6.06M	25.16M	37.63M	49.95M	105.88M	114.92M	64.6M	52.76M	40.37M
Days Payables Outstanding	141.84	64.39	204.25	251.83	189.88	294	345.73	186.09	136.22	100.07
Short-Term Debt	14.74M	31.3M	22.83M	34.24M	50.13M	0	0	0	0	0
Deferred Revenue (Current)	923K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0
Other Current Liabilities	4.28M	5.8M	5.16M	72M	16.59M	28.79M	45.6M	35.64M	185.23M	139.58M
Current Ratio	2.83x	1.92x	1.41x	2.40x	3.53x	2.86x	2.37x	2.66x	2.80x	3.31x
Quick Ratio	2.46x	1.65x	1.13x	2.04x	3.21x	2.25x	1.74x	1.77x	1.80x	2.39x
Cash Conversion Cycle	168.48	209.51	132.79	240.91	200.83	322.32	462.69	602.3	690.33	506.8
Total Non-Current Liabilities+	251.93M	99.81M	118.17M	76.12M	31.7M	31.07M	30.28M	31.37M	20.31M	19.22M
Long-Term Debt	230.12M	85.16M	99.83M	46.11M	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	9.44M	9.15M	8.58M	10.02M	8.74M	7.72M
Deferred Tax Liabilities	8.17M	0	1.74M	0	0	0	0	0	0	0
Other Non-Current Liabilities	8.51M	710K	1.15M	10.52M	3.75M	6.21M	7.65M	8.21M	9.06M	11.5M
Total Liabilities	302.65M	176.06M	226.7M	233.38M	273.95M	338.52M	400.97M	290.85M	279.59M	199.17M
Total Debt+	244.86M	116.45M	122.66M	80.35M	59.57M	9.15M	8.58M	10.02M	8.74M	7.72M
Net Debt	137.9M	18.2M	49.02M	-168.88M	-585.01M	-177.81M	-210.88M	-207.65M	-190.51M	-113.31M
Debt / Equity	-	-	-	0.53x	0.10x	0.01x	0.01x	0.02x	0.02x	0.02x
Debt / EBITDA	-	-	-	-	-	-	0.64x	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-15.79x	-	-	-
Interest Coverage	-4.90x	-3.51x	-4.66x	-12.20x	-3.66x	-7.55x	81.41x	-7057.93x	-8448.50x	-13113.86x
Total Equity+	-129.19M	-9.06M	-65.1M	152.33M	608.26M	627.5M	667.1M	595.33M	552.1M	486.18M
Equity Growth %	-0.46%	0.93%	-6.19%	3.34%	2.99%	0.03%	0.06%	-0.11%	-0.07%	-0.12%
Book Value per Share	-0.72	-0.04	-0.24	0.51	1.78	1.64	1.66	1.48	1.35	1.18
Total Shareholders' Equity	-129.19M	-9.06M	-65.1M	152.33M	608.26M	627.5M	667.1M	595.33M	552.1M	486.18M
Common Stock	149.98M	207.17M	208.77M	246.66M	269.17M	290.12M	294.03M	299M	302.76M	305.3M
Retained Earnings	-1.12B	-1.2B	-1.27B	-1.39B	-1.41B	-1.43B	-1.42B	-1.53B	-1.59B	-1.67B
Treasury Stock	-411K	-1.51M	-4.23M	-10.41M	-35.9M	-51.08M	-60.73M	-61.77M	-63.75M	-65.33M
Accumulated OCI	-754K	0	-816K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-84.75M	-71.81M	-32.84M	-94.7M	-9.37M	-21.75M	-66.53M	-179.98M	6.91M	-31.02M
Operating CF Margin %	-1.04%	-0.55%	-0.18%	-0.41%	-0.02%	-0.04%	-0.11%	-0.49%	0.02%	-0.14%
Operating CF Growth %	-0.17%	0.15%	0.54%	-1.88%	0.9%	-1.32%	-2.06%	-1.71%	1.04%	-5.49%
Net Income	-115.2M	-86.35M	-67.86M	-116.44M	-22.64M	-18M	7.73M	-105.74M	-59.34M	-82.18M
Depreciation & Amortization	812K	783K	708K	669K	859K	2.04M	2.86M	3.09M	2.98M	3.01M
Stock-Based Compensation	13.88M	13.61M	13.96M	18.81M	30.92M	45.81M	0	0	0	17.7M
Deferred Taxes	-4.25M	8.8M	11.08M	0	0	0	0	0	0	0
Other Non-Cash Items	7.32M	-327K	2.33M	2.18M	1.64M	2.24M	38.86M	26.67M	12M	-5.73M
Working Capital Changes	12.69M	-8.33M	6.95M	84K	-20.14M	-53.83M	-115.98M	-104.01M	51.27M	36.17M
Change in Receivables	-5.98M	-6.17M	-25.33M	-21.2M	-49.91M	-39.47M	-8.34M	32.98M	-2.33M	11.22M
Change in Inventory	-5.25M	-1.52M	-9.75M	-27.54M	-18.97M	-112.09M	-167.05M	-36.4M	56.34M	105.44M
Change in Payables	10.49M	8.71M	40.27M	37.6M	65.91M	114.74M	51.51M	-102.67M	-164.63K	-77.02M
Cash from Investing+	-28K	-21K	-12K	-58K	-2.48M	-376.96M	104.09M	175.18M	-25.62M	-45.98M
Capital Expenditures	-28K	-21K	-12K	-58K	-2.48M	-252K	0	-598.63K	-535.07K	0
CapEx % of Revenue	0%	0%	0%	0%	0.01%	0%	0%	0%	0%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-28K	-21K	0	-58K	0	0	0	0	0	0
Cash from Financing+	72.2M	63.13M	8.23M	271.25M	409.61M	-58.91M	-5.07M	-378.77K	230.89K	-1.44M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	2.44M	-1.49M	-569K	21.1M	1.16M	-8.57M	-9.64M	-1.04M	-1.99M	-1.57M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-84.78M	-71.84M	-32.85M	-94.76M	-11.84M	-22M	-66.53M	-179.98M	6.88M	-31.02M
FCF Margin %	-1.04%	-0.55%	-0.18%	-0.41%	-0.03%	-0.04%	-0.11%	-0.49%	0.02%	-0.14%
FCF Growth %	-0.17%	0.15%	0.54%	-1.88%	0.88%	-0.86%	-2.02%	-1.71%	1.04%	-5.51%
FCF per Share	-0.47	-0.34	-0.12	-0.32	-0.03	-0.06	-0.17	-0.45	0.02	-0.08
FCF Conversion (FCF/Net Income)	0.74x	0.83x	0.48x	0.81x	0.41x	1.21x	-8.61x	1.70x	-0.12x	0.38x
Interest Paid	12.56M	17.08M	17.24M	21.53M	4.59M	2.04M	0	0	0	0
Taxes Paid	711K	1.46M	1.75M	850K	67K	207K	0	0	0	3.98M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-266.98%	-5.95%	-2.91%	1.19%	-16.76%	-10.3%	-15.83%
Return on Invested Capital (ROIC)	-534.26%	-551.54%	-	-	-543.64%	-6.23%	1.74%	-18.82%	-13.53%	-18.75%
Gross Margin	65.9%	73.58%	75.18%	76.2%	77.66%	78.59%	79.2%	65.68%	53.94%	35.6%
Net Margin	-140.91%	-66.38%	-37.47%	-50.8%	-5.27%	-2.93%	1.33%	-28.66%	-19.26%	-35.95%
Debt / Equity	-	-	-	0.53x	0.10x	0.01x	0.01x	0.02x	0.02x	0.02x
Interest Coverage	-4.90x	-3.51x	-4.66x	-12.20x	-3.66x	-7.55x	81.41x	-7057.93x	-8448.50x	-13113.86x
FCF Conversion	0.74x	0.83x	0.48x	0.81x	0.41x	1.21x	-8.61x	1.70x	-0.12x	0.38x
Revenue Growth	50.84%	59.11%	39.22%	26.56%	87.49%	42.89%	-5.03%	-36.69%	-16.87%	-25.51%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Product	228.37M	427.39M	607.02M	580.32M	366.51M	285.3M	204.59M
Product Growth	-	87.15%	42.03%	-4.40%	-36.84%	-22.16%	-28.29%
Licensing And Royalty	-	-	7.04M	2.87M	2.68M	21.61M	24.02M
Licensing And Royalty Growth	-	-	-	-59.25%	-6.45%	705.82%	11.16%
License	843K	2.36M	-	-	-	-	-
License Growth	-	180.43%	-	-	-	-	-

Revenue by Geography

	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	-	-	-	166.7M
UNITED STATES Growth	-	-	-	-	-	-	-
Europe	-	-	-	-	-	-	13.66M
Europe Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Amarin Corporation plc (AMRN) reported $225.6M in revenue for fiscal year 2024.

Amarin Corporation plc (AMRN) saw revenue decline by 25.5% over the past year.

Amarin Corporation plc (AMRN) reported a net loss of $86.2M for fiscal year 2024.

Dividend & Returns

Amarin Corporation plc (AMRN) has a return on equity (ROE) of -15.8%. Negative ROE indicates the company is unprofitable.

Amarin Corporation plc (AMRN) had negative free cash flow of $21.9M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Amarin Corporation plc (AMRN) 10-Year Financial Performance & Capital Metrics

AMRN • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

Revenue $229M -25.5%
EBITDA -$89M -37.4%
Net Income -$82M -39.0%
EPS (Diluted) -0.20 -33.3%
Gross Margin 35.6% -34.0%
EBITDA Margin -38.84% -84.4%
Operating Margin -40.15% -82.3%
Net Margin -35.95% -86.6%
ROE -15.83% -53.6%
ROIC -18.75% -38.6%
Debt/Equity 0.02 +0.4%
Interest Coverage -13113.86 -55.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 11.9% over 5 years
✗Expensive at 12.8x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y15.48%

5Y-11.86%

3Y-26.81%

TTM-6.67%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-118.79%

EPS CAGR

10Y-

5Y-

3Y-

TTM-910.42%

ROCE

10Y Avg-33.06%

5Y Avg-9.16%

3Y Avg-14.77%

Latest-17.03%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.99B	41.39	532.01		31.18%	-33.24%	3.76%	0.14
GNFTGenfit S.A.	310.02M	6.20	206.67	134.56%	-14.12%	-31.42%	4.59%	0.90
GYREGyre Therapeutics, Inc.	750.44M	7.79	155.80	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.78M	4.56	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	129.59M	6.03	-1.08	-100%		-89.15%		0.10
GLTOGalecto, Inc.	37.28M	23.30	-1.26			-237.68%		0.00
IVAInventiva S.A.	1.1B	5.71	-1.61	-47.37%	-13.75%
GALTGalectin Therapeutics Inc.	197.93M	3.07	-4.04

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	81.76M	130.08M	181.1M	229.21M	429.75M	614.06M	583.19M	369.19M	306.91M	228.61M
Revenue Growth %	0.51%	0.59%	0.39%	0.27%	0.87%	0.43%	-0.05%	-0.37%	-0.17%	-0.26%
Cost of Goods Sold+	27.88M	34.36M	44.95M	54.54M	96.02M	131.44M	121.33M	126.71M	141.37M	147.23M
COGS % of Revenue	0.34%	0.26%	0.25%	0.24%	0.22%	0.21%	0.21%	0.34%	0.46%	0.64%
Gross Profit+	53.88M	95.72M	136.15M	174.67M	333.74M	482.62M	461.86M	242.48M	165.54M	81.38M
Gross Margin %	0.66%	0.74%	0.75%	0.76%	0.78%	0.79%	0.79%	0.66%	0.54%	0.36%
Gross Profit Growth %	0.6%	0.78%	0.42%	0.28%	0.91%	0.45%	-0.04%	-0.47%	-0.32%	-0.51%
Operating Expenses+	152.1M	161.35M	181.71M	282.9M	358.01M	502.27M	451.36M	348.35M	233.13M	173.18M
OpEx % of Revenue	1.86%	1.24%	1%	1.23%	0.83%	0.82%	0.77%	0.94%	0.76%	0.76%
Selling, General & Admin	101.05M	111.37M	134.55M	227M	323.62M	463.31M	408.33M	304.42M	199.94M	152.31M
SG&A % of Revenue	1.24%	0.86%	0.74%	0.99%	0.75%	0.75%	0.7%	0.82%	0.65%	0.67%
Research & Development	51.06M	49.98M	47.16M	55.9M	34.39M	38.96M	29.31M	30.41M	22.22M	20.87M
R&D % of Revenue	0.62%	0.38%	0.26%	0.24%	0.08%	0.06%	0.05%	0.08%	0.07%	0.09%
Other Operating Expenses	-9K	-482K	74K	-326K	0	104K	13.72M	13.53M	10.97M	0
Operating Income+	-98.22M	-65.63M	-45.55M	-108.22M	-24.28M	-19.66M	10.5M	-105.87M	-67.59M	-91.8M
Operating Margin %	-1.2%	-0.5%	-0.25%	-0.47%	-0.06%	-0.03%	0.02%	-0.29%	-0.22%	-0.4%
Operating Income Growth %	-0.02%	0.33%	0.31%	-1.38%	0.78%	0.19%	1.53%	-11.08%	0.36%	-0.36%
EBITDA+	-97.41M	-64.85M	-44.84M	-107.56M	-23.42M	-17.6M	13.36M	-102.77M	-64.62M	-88.78M
EBITDA Margin %	-1.19%	-0.5%	-0.25%	-0.47%	-0.05%	-0.03%	0.02%	-0.28%	-0.21%	-0.39%
EBITDA Growth %	-0.02%	0.33%	0.31%	-1.4%	0.78%	0.25%	1.76%	-8.69%	0.37%	-0.37%
D&A (Non-Cash Add-back)	812K	777.59K	715.59K	667.87K	859K	2.05M	2.86M	3.1M	2.96M	3.01M
EBIT	-98.11M	-57.31M	-45.05M	-107.3M	-15.86M	-14.76M	11.42M	-103.79M	-53.88M	-77.19M
Net Interest Income+	-20.05M	-18.44M	-9.34M	-7.8M	1.87M	2.3M	1.09M	2.8M	11.86M	13.4M
Interest Income	0	234K	429K	1.07M	8.5M	4.9M	1.22M	2.82M	11.86M	13.4M
Interest Expense	20.05M	18.68M	9.77M	8.87M	6.63M	2.6M	129K	15K	8K	7K
Other Income/Expense	-20.07M	-10.76M	-9.26M	-8.12M	1.8M	2.4M	789K	2.06M	13.92M	14.6M
Pretax Income+	-118.29M	-76.38M	-55.41M	-116.35M	-22.48M	-17.25M	11.29M	-103.81M	-53.67M	-77.2M
Pretax Margin %	-1.45%	-0.59%	-0.31%	-0.51%	-0.05%	-0.03%	0.02%	-0.28%	-0.17%	-0.34%
Income Tax+	-3.09M	9.97M	13.05M	96K	164K	745K	3.56M	2M	5.44M	4.98M
Effective Tax Rate %	0.97%	1.13%	1.22%	1%	1.01%	1.04%	0.68%	1.02%	1.1%	1.06%
Net Income+	-115.2M	-86.35M	-67.86M	-116.44M	-22.64M	-18M	7.73M	-105.8M	-59.11M	-82.18M
Net Margin %	-1.41%	-0.66%	-0.37%	-0.51%	-0.05%	-0.03%	0.01%	-0.29%	-0.19%	-0.36%
Net Income Growth %	-1.04%	0.25%	0.21%	-0.72%	0.81%	0.21%	1.43%	-14.69%	0.44%	-0.39%
Net Income (Continuing)	-115.2M	-86.35M	-68.59M	-116.44M	-22.64M	-18M	7.73M	-105.8M	-59.11M	-82.18M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.83	-0.41	-0.25	-0.39	-0.07	-0.05	0.02	-0.26	-0.15	-0.20
EPS Growth %	-1.31%	0.51%	0.39%	-0.56%	0.83%	0.24%	1.38%	-14.54%	0.42%	-0.33%
EPS (Basic)	-0.83	-0.41	-0.25	-0.39	-0.07	-0.05	0.02	-0.26	-0.15	-0.20
Diluted Shares Outstanding	180.65M	211.87M	270.65M	297.24M	342.54M	381.76M	402.48M	401.15M	407.65M	410.94M
Basic Shares Outstanding	179.59M	210.61M	270.65M	297.24M	342.54M	360M	395.99M	401.15M	394.08M	410.94M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	143.52M	146.33M	153.27M	378M	855M	879.23M	878.73M	689.1M	724.98M	595.4M
Cash & Short-Term Investments	106.96M	98.25M	73.64M	249.23M	644.59M	500.93M	454.13M	309.36M	320.66M	294.22M
Cash Only	106.96M	98.25M	73.64M	249.23M	644.59M	186.96M	219.45M	217.67M	199.25M	121.04M
Short-Term Investments	0	0	0	0	0	313.97M	234.67M	91.69M	121.41M	173.18M
Accounts Receivable	13.83M	19.98M	45.32M	66.52M	116.43M	154.57M	163.65M	130.99M	133.56M	122.28M
Days Sales Outstanding	61.73	56.08	91.33	105.93	98.89	91.88	102.43	129.5	158.84	195.23
Inventory	18.98M	20.51M	30.26M	57.8M	76.77M	188.86M	234.68M	228.73M	258.62M	166.05M
Days Inventory Outstanding	248.59	217.82	245.7	386.81	291.82	524.45	706	658.89	667.71	411.65
Other Current Assets	600K	600K	600K	1.5M	3.91M	3.92M	3.92M	20.02M	525K	12.85M
Total Non-Current Assets+	29.94M	20.67M	8.33M	7.72M	27.2M	86.79M	189.34M	197.08M	106.7M	89.95M
Property, Plant & Equipment	243K	78K	28K	63K	10.87M	10.07M	9.09M	9.95M	8.42M	7.61M
Fixed Asset Turnover	336.44x	1667.74x	6468.00x	3638.32x	39.53x	60.98x	64.19x	37.11x	36.43x	30.05x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	9.42M	8.77M	8.13M	7.48M	15.26M	13.82M	23.55M	21.78M	19.3M	16.39M
Long-Term Investments	0	0	-1.74M	0	0	62.47M	35M	1.27M	0	0
Other Non-Current Assets	2.04M	741K	174K	174K	1.07M	432K	121.71M	164.08M	78.97M	65.95M
Total Assets+	173.46M	167M	161.6M	385.71M	882.21M	966.02M	1.07B	886.18M	831.68M	685.35M
Asset Turnover	0.47x	0.78x	1.12x	0.59x	0.49x	0.64x	0.55x	0.42x	0.37x	0.33x
Asset Growth %	0.01%	-0.04%	-0.03%	1.39%	1.29%	0.1%	0.11%	-0.17%	-0.06%	-0.18%
Total Current Liabilities+	50.72M	76.25M	108.53M	157.26M	242.25M	307.44M	370.68M	259.48M	259.28M	179.95M
Accounts Payable	10.83M	6.06M	25.16M	37.63M	49.95M	105.88M	114.92M	64.6M	52.76M	40.37M
Days Payables Outstanding	141.84	64.39	204.25	251.83	189.88	294	345.73	186.09	136.22	100.07
Short-Term Debt	14.74M	31.3M	22.83M	34.24M	50.13M	0	0	0	0	0
Deferred Revenue (Current)	923K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0
Other Current Liabilities	4.28M	5.8M	5.16M	72M	16.59M	28.79M	45.6M	35.64M	185.23M	139.58M
Current Ratio	2.83x	1.92x	1.41x	2.40x	3.53x	2.86x	2.37x	2.66x	2.80x	3.31x
Quick Ratio	2.46x	1.65x	1.13x	2.04x	3.21x	2.25x	1.74x	1.77x	1.80x	2.39x
Cash Conversion Cycle	168.48	209.51	132.79	240.91	200.83	322.32	462.69	602.3	690.33	506.8
Total Non-Current Liabilities+	251.93M	99.81M	118.17M	76.12M	31.7M	31.07M	30.28M	31.37M	20.31M	19.22M
Long-Term Debt	230.12M	85.16M	99.83M	46.11M	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	9.44M	9.15M	8.58M	10.02M	8.74M	7.72M
Deferred Tax Liabilities	8.17M	0	1.74M	0	0	0	0	0	0	0
Other Non-Current Liabilities	8.51M	710K	1.15M	10.52M	3.75M	6.21M	7.65M	8.21M	9.06M	11.5M
Total Liabilities	302.65M	176.06M	226.7M	233.38M	273.95M	338.52M	400.97M	290.85M	279.59M	199.17M
Total Debt+	244.86M	116.45M	122.66M	80.35M	59.57M	9.15M	8.58M	10.02M	8.74M	7.72M
Net Debt	137.9M	18.2M	49.02M	-168.88M	-585.01M	-177.81M	-210.88M	-207.65M	-190.51M	-113.31M
Debt / Equity	-	-	-	0.53x	0.10x	0.01x	0.01x	0.02x	0.02x	0.02x
Debt / EBITDA	-	-	-	-	-	-	0.64x	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-15.79x	-	-	-
Interest Coverage	-4.90x	-3.51x	-4.66x	-12.20x	-3.66x	-7.55x	81.41x	-7057.93x	-8448.50x	-13113.86x
Total Equity+	-129.19M	-9.06M	-65.1M	152.33M	608.26M	627.5M	667.1M	595.33M	552.1M	486.18M
Equity Growth %	-0.46%	0.93%	-6.19%	3.34%	2.99%	0.03%	0.06%	-0.11%	-0.07%	-0.12%
Book Value per Share	-0.72	-0.04	-0.24	0.51	1.78	1.64	1.66	1.48	1.35	1.18
Total Shareholders' Equity	-129.19M	-9.06M	-65.1M	152.33M	608.26M	627.5M	667.1M	595.33M	552.1M	486.18M
Common Stock	149.98M	207.17M	208.77M	246.66M	269.17M	290.12M	294.03M	299M	302.76M	305.3M
Retained Earnings	-1.12B	-1.2B	-1.27B	-1.39B	-1.41B	-1.43B	-1.42B	-1.53B	-1.59B	-1.67B
Treasury Stock	-411K	-1.51M	-4.23M	-10.41M	-35.9M	-51.08M	-60.73M	-61.77M	-63.75M	-65.33M
Accumulated OCI	-754K	0	-816K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-84.75M	-71.81M	-32.84M	-94.7M	-9.37M	-21.75M	-66.53M	-179.98M	6.91M	-31.02M
Operating CF Margin %	-1.04%	-0.55%	-0.18%	-0.41%	-0.02%	-0.04%	-0.11%	-0.49%	0.02%	-0.14%
Operating CF Growth %	-0.17%	0.15%	0.54%	-1.88%	0.9%	-1.32%	-2.06%	-1.71%	1.04%	-5.49%
Net Income	-115.2M	-86.35M	-67.86M	-116.44M	-22.64M	-18M	7.73M	-105.74M	-59.34M	-82.18M
Depreciation & Amortization	812K	783K	708K	669K	859K	2.04M	2.86M	3.09M	2.98M	3.01M
Stock-Based Compensation	13.88M	13.61M	13.96M	18.81M	30.92M	45.81M	0	0	0	17.7M
Deferred Taxes	-4.25M	8.8M	11.08M	0	0	0	0	0	0	0
Other Non-Cash Items	7.32M	-327K	2.33M	2.18M	1.64M	2.24M	38.86M	26.67M	12M	-5.73M
Working Capital Changes	12.69M	-8.33M	6.95M	84K	-20.14M	-53.83M	-115.98M	-104.01M	51.27M	36.17M
Change in Receivables	-5.98M	-6.17M	-25.33M	-21.2M	-49.91M	-39.47M	-8.34M	32.98M	-2.33M	11.22M
Change in Inventory	-5.25M	-1.52M	-9.75M	-27.54M	-18.97M	-112.09M	-167.05M	-36.4M	56.34M	105.44M
Change in Payables	10.49M	8.71M	40.27M	37.6M	65.91M	114.74M	51.51M	-102.67M	-164.63K	-77.02M
Cash from Investing+	-28K	-21K	-12K	-58K	-2.48M	-376.96M	104.09M	175.18M	-25.62M	-45.98M
Capital Expenditures	-28K	-21K	-12K	-58K	-2.48M	-252K	0	-598.63K	-535.07K	0
CapEx % of Revenue	0%	0%	0%	0%	0.01%	0%	0%	0%	0%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-28K	-21K	0	-58K	0	0	0	0	0	0
Cash from Financing+	72.2M	63.13M	8.23M	271.25M	409.61M	-58.91M	-5.07M	-378.77K	230.89K	-1.44M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	2.44M	-1.49M	-569K	21.1M	1.16M	-8.57M	-9.64M	-1.04M	-1.99M	-1.57M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-84.78M	-71.84M	-32.85M	-94.76M	-11.84M	-22M	-66.53M	-179.98M	6.88M	-31.02M
FCF Margin %	-1.04%	-0.55%	-0.18%	-0.41%	-0.03%	-0.04%	-0.11%	-0.49%	0.02%	-0.14%
FCF Growth %	-0.17%	0.15%	0.54%	-1.88%	0.88%	-0.86%	-2.02%	-1.71%	1.04%	-5.51%
FCF per Share	-0.47	-0.34	-0.12	-0.32	-0.03	-0.06	-0.17	-0.45	0.02	-0.08
FCF Conversion (FCF/Net Income)	0.74x	0.83x	0.48x	0.81x	0.41x	1.21x	-8.61x	1.70x	-0.12x	0.38x
Interest Paid	12.56M	17.08M	17.24M	21.53M	4.59M	2.04M	0	0	0	0
Taxes Paid	711K	1.46M	1.75M	850K	67K	207K	0	0	0	3.98M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-266.98%	-5.95%	-2.91%	1.19%	-16.76%	-10.3%	-15.83%
Return on Invested Capital (ROIC)	-534.26%	-551.54%	-	-	-543.64%	-6.23%	1.74%	-18.82%	-13.53%	-18.75%
Gross Margin	65.9%	73.58%	75.18%	76.2%	77.66%	78.59%	79.2%	65.68%	53.94%	35.6%
Net Margin	-140.91%	-66.38%	-37.47%	-50.8%	-5.27%	-2.93%	1.33%	-28.66%	-19.26%	-35.95%
Debt / Equity	-	-	-	0.53x	0.10x	0.01x	0.01x	0.02x	0.02x	0.02x
Interest Coverage	-4.90x	-3.51x	-4.66x	-12.20x	-3.66x	-7.55x	81.41x	-7057.93x	-8448.50x	-13113.86x
FCF Conversion	0.74x	0.83x	0.48x	0.81x	0.41x	1.21x	-8.61x	1.70x	-0.12x	0.38x
Revenue Growth	50.84%	59.11%	39.22%	26.56%	87.49%	42.89%	-5.03%	-36.69%	-16.87%	-25.51%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Product	228.37M	427.39M	607.02M	580.32M	366.51M	285.3M	204.59M
Product Growth	-	87.15%	42.03%	-4.40%	-36.84%	-22.16%	-28.29%
Licensing And Royalty	-	-	7.04M	2.87M	2.68M	21.61M	24.02M
Licensing And Royalty Growth	-	-	-	-59.25%	-6.45%	705.82%	11.16%
License	843K	2.36M	-	-	-	-	-
License Growth	-	180.43%	-	-	-	-	-

Revenue by Geography

	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	-	-	-	166.7M
UNITED STATES Growth	-	-	-	-	-	-	-
Europe	-	-	-	-	-	-	13.66M
Europe Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Amarin Corporation plc (AMRN) reported $225.6M in revenue for fiscal year 2024.

Amarin Corporation plc (AMRN) saw revenue decline by 25.5% over the past year.

Amarin Corporation plc (AMRN) reported a net loss of $86.2M for fiscal year 2024.

Dividend & Returns

Amarin Corporation plc (AMRN) has a return on equity (ROE) of -15.8%. Negative ROE indicates the company is unprofitable.

Amarin Corporation plc (AMRN) had negative free cash flow of $21.9M in fiscal year 2024, likely due to heavy capital investments.